Generalized Anxiety Disorder

Operational Definition

- A. Excessive anxiety and worry (apprehensive expectation) about two (or more) domains of activities or events
- B. The excessive anxiety and worry occur on more days than not for three months or more
- C. The anxiety and worry are associated with one or more of the following symptoms:

Operational Definition

- 1. Restlessness or feeling keyed up or on edge*
- 2. Being easily fatigued
- 3. Difficulty concentrating or mind going blank
- 4. Irritability
- 5. Muscle tension*
- 6. Sleep disturbance

* = key symptor

Operational Definition

- D. The anxiety and worry are associated with one (or more) of the following behaviors:
 - 1. Marked avoidance of situations in which a negative outcome could occur
 - 2. Marked time and effort preparing for situations in which a negative outcome could occur
 - 3. Marked procrastination in behavior or decisionmaking due to worries
 - 4. Repeatedly seeking reassurance due to worries

Operational Definition

- E. The focus of the anxiety and worry are not restricted to symptoms of another disorder.
- F. The anxiety, worry, or physical symptoms cause clinically significant distress or impairment in social, occupational, or other important areas of functioning.
- G. The disturbance is not due to the direct physiological effects of a substance or a general medical condition

GAD Prevalence

- Very frequently observed in epidemiological studies
- 1.5-3% current, 4-7% lifetime rates in USA
- 1.2-1.9% current, 4.3-5.9% lifetime in Europe

Tyler & Baldwin (2006); van der Heiden et al. (2011)

GAD Course

- Generally considered a chronic problem, but newer research shows
 - Under 20% chronicity
 - Much higher remission than assumed
- Still, poor prognosis without treatment, and only 40% seek treatment

Tyler & Baldwin (2006); van der Heiden et al. (2011)

Gender Differences

Prevalence is doubled in females:
 Lifetime ratio of 1 male to 1.9 females

- 12-month rate of 1 male to 2.2 females
- Differing comorbidity rates
 - More SUD and ASPD in males
 - More mood and anxiety disorders in females
- Higher disability rates in females

Vesaga-Lopez et al. (2008)

SES & Cultural Differences

- Being female, middle-aged, non-married, and low income increases risk
- Being Asian, Hispanic, or Black decreases risk
- Eastern cultures may show more somatic symptoms than Western

Grant et al. (2008)

Comorbidity

- Extraordinarily high, with studies showing 90% in general population, 45-98% in clinical studies
- Major depression is most common comorbid, at 60% of patients
- Other anxiety disorders, sleep problems, chronic pain, and somatic symptoms common

Tyler & Baldwin (2006); van der Heiden et al. (2011)

Comorbidity

- Some have questioned if GAD is a disorder or a prodrome/symptom of others
- Appears to be it's own problem, based on:
 - Reliable and valid diagnosis
 - Non-comorbid GAD seen not infrequently
 - High comorbid rates may be artifact

van der Heiden et al. (2011)

Comorbidity

- Worry and avoidance are features of most anxiety disorders, careful screening is needed
- Table 1 in van der Heiden et al. (2011) provides excellent differential diagnosis samples

van der Heiden et al. (2011)

Impact of GAD

- Higher severity of social and occupation impairment than other anxiety disorders
- Decreases in QoL similar to mood disorders, diabetes, hypertension, and CHF
- High rate and cost of non-MH physician visits;
 ½ patients with IBS meet criteria for GAD

Andrews et al. (2010); Grant et al. (2008)

Etiology

- Anxiety is biologically useful, maybe especially so for females
- May share genetic risk factors with MDD, with environment shaping outward behaviors
- Neuroticism, which is genetically influenced, and GAD are strongly correlated

Tyler & Baldwin (2006)

GAD as GWD


- Worry is the defining feature of GAD
- Average person spends 15% of day worrying; person with GAD spends over 60% on average
- An avoidant coping strategy, maintained via dual types of reinforcements

Andrews et al. (2010)


GAD as GWD

- Positive reinforcement through decreased physiological and emotional reactivity
- Negative reinforcement because the "worries" or catastrophes generally do not come true
- Causes people to see worry as a good thing

van der Heiden et al. (2011)









GAD as GWD

- People with GAD tend to view worry as positive and beneficial
 - Superstitious avoidance of catastrophe
 - Actual avoidance of catastrophe
 - Avoidance of deeper emotions
 - Coping and preparation
 - Motivating device

Andrews et al. (2010)

GAD as GWD

- Worry suppresses intensity to responses, but also has many negative consequences
- It highly increases incidence of intrusive imagery and sense of uncontrollability
- This makes one both a) more likely to worry and b) increasingly impaired

Andrews et al. (2010)

Intolerance of Uncertainty

- Another hallmark of GAD, may actually be *why* people engage in avoidant worrying
- View uncertain situations as
 - Stressful and upsetting
 - Unfair
 - Negative and should be avoided
 - Interfering with one's ability to function

Andrews et al. (2010)

Checking In

- Not the same as in OCD, where the focus is on checking objects
- In GAD, the checking focuses on achievement and relationships
- Often involves reassurance seeking and procrastination

Andrews et al. (2010)

GAD Treatment

- Similar effect sizes for psychological (0.7) and pharmacological (0.6) treatments
- Lack of access to trained clinicians, however, hampers outcome rates
- Leads to majority of GAD patients being treatment with medications

Tyler & Baldwin (2006)


Pharmacology for GAD

- Benzodiazepines show better immediate impact, but antidepressants better long term
- Choice of AD would be best guided by symptom profile
- Little evidence, though, to suggest long-term use and evidence of high relapse

Baldwin et al. (2011); Tyler & Baldwin (2006)

Meds	Treatment	Rankings
		- 0-

Ranking	Response*	Remission ⁺	Withdrawal‡
1	Fluoxetine	Fluoxetine	Sertraline
2	Lorazepam	Escitalopram	Pregabalin
3	Duloxetine	Venlafaxine	Fluoxetine
4	Sertraline	Paroxetine	Paroxetine
5	Paroxetine	Sertraline	Tiagabine
6	Pregabalin	Duloxetine	Venlafaxine
7	Venlafaxine	Tiagabine	Escitalopram
8	Escitalopram	NA	Duloxetine
9	Tiagabine	NA	Lorazepam
*Proportion of pat †Proportion of pat	(not all studies reported on this ients who experienced reductio tients with final HAM-A score ≤7 tients withdrawing from study b	n of ≥50% from their baseline I 7.	Hamilton anxiety scale score.
			Baldwin et al. (201





CBT for GAD

- Outperforms other therapies at both posttreatment and long-term follow-up
- No evidence for long-term treatments being superior to short-term ones (8-10 sessions)
- Superior to meds in relapse prevention, with improvements up to 2 years post-treatment

CBT for GAD

- Four traditional components
 - 1. Self-monitoring
 - 2. Relaxation training
 - 3. Cognitive therapy
 - 4. Rehearsal of #'s 2 and 3
- Newer research has also added interpersonal and emotional processing techniques

Borkovec et al. (2004)

Self-Monitoring

- Teaches patients to objectively observe their anxious responses and its triggers
- Earlier a patient can identify worry, the more effective the deployment of coping responses
- Can use both in-session techniques and homework to facilitate this

Borkovec et al. (2004)

Applied Relaxation Training

- Trained in PMR in session, then practice twice daily to achieve mastery
- Can also use DB, meditation, pleasant imagery
- Once mastery is obtained, instructed to use during *in vivo* anxious situations

Borkovec et al. (2004)

Rehearsal of Coping Responses

- In session, therapists attempt to elicit worry from client, who then practices PMR or CR
- Key to use intense imagery, not just verbal descriptions, to induce higher anxiety levels

Borkovec et al. (2004)

Other CBT Tools

- Stimulus-control techniques (Worry Time)
- Correct information about worry's "benefits"
- Teach problem-solving skills
- Exposure to worrying thoughts via recording

Borkovec et al. (2004)

CBT Outcomes

- Aggregated results show strong effect sizes – 1.09 compared to WLC
- Gains maintained at 6 and 12 months
- Very low dropout rates (9%), no association between med status and response

Borkovec et al. (2004)

CBT Outcomes

- Still, only about 50% of patients return to normal anxiety levels
- This led to attempts to find supplementary, treatment boosting add-ons to CBT
 - Emotional processing avoidance
 - Interpersonal problems

CBT + I/EP

- Promising results initially (Newman et al., 2004)
- More well controlled study found little difference at post-treatment or follow-up – Very large within-group ES (1.51 & 1.9)
 - Similar rates of non-GAD (63.6% & 75%)
- May work better only for certain patients

Newman et al. (2011)

Newman et al. (2011)